Discover BD SurePath™ Liquid-based Pap Test

The BD SurePath™ Liquid-based Pap Test is an FDA and CE-marked cytology method with higher cervical disease detection and a lower unsatisfactory rate compared to conventional cytology and other liquid-based cytology (LBC) devices.1

Simple and efficient cell collection that ensures sample quality

Visual
  • The head of the collection device is deposited directly into the BD SurePath™ Collection Vial so 100% of the collected cells are sent to the laboratory for analysis – unlike the rinsing method which can result in up to 37% of cells being discarded.2,3
  • The cells are preserved in an ethanol solution for optimal slide preparation in the lab.4
  • The same sample can be used for cytology testing, immunocytochemistry, and HPV testing.4-6

See how BD SurePath™ can help you to collect cervical samples of high quality for cytology and molecular testing.

Video Player is loading.
Current Time 0:00
Duration 2:12
Loaded: 7.46%
Stream Type LIVE
Remaining Time 2:12
 
1x
    • Chapters
    • descriptions off, selected
    • subtitles off, selected
    • en (Main), selected

    Unique and standardised sample processing that offers homogenous slides

    • BD SurePath™ Liquid-based Pap Test uses a proprietary cell enrichment process to eliminate blood, inflammatory cells, mucus and other debris. Only the most diagnostically relevant material is presented on the slide, offering a clear background.7,8
    • Automated slide preparation with on-board staining results in a 13 mm deposition area and uniform distribution of the cells in a thin layer.9

    Accurate and definitive results that enhance patient care

    Women* who are screened with BD SurePath™ Liquid-based Pap Test have a higher chance of having their precancerous lesions detected than women who are screened with either conventional cytology or other LBC devices.2

    Compared to conventional cytology, BD SurePath™ Liquid-based Pap Test resulted in:1
    -58% in unsatisfactory reports
    -29% in ASC-US/LSIL ratio
    +64% in HSIL+ detection
    +107% in LSIL+ detection

    Decrease unsatisfactory reports

    Increase the detection of cervical precancerous lesions

    Decrease the risk of cervical cancer in the follow-up period

    The BD SurePath™ Liquid-based Pap Test is your trusted partner from sample collection to result reporting.

    BD solutions for
    HPV testing

    LEARN MORE

    ASC-US, atypical squamous cells of undetermined significance; FDA, Food and Drug Administration; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesions; LBC, liquid-based cytology; LSIL, low-grade squamous intraepithelial lesions; Pap, Papanicolaou; SIL, squamous intraepithelial lesions.

    1. Fremont-Smith M et al. Cancer. 2004;102(5):269–79.
    2. Nance KV. Diagn Cytopathol. 2007;35(3):148–53.
    3. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–74.
    4. BD SurePath™ Collection Vial Package Insert (500017013).
    5. CINtec® PLUS Cytology Kit Package Insert.
    6. BD Onclarity™ HPV Assay Package Insert (8089899).
    7. Sweeney BJ et al. Cancer Cytopathol. 2006; 108(1): 27–31
    8. Kenyon S et al. Cancer Cytopathol. 2010;118(5):244–9.
    9. BD Totalys™ SlidePrep Instrument User’s Manual (500005570).
    10. Ransdell JS et al. Cancer Cytopathol. 1997;81(3):139–43.
    11. Nygård JF et al. J Med Screen. 2004;11(2):70–6.
    12. Rozemeijer K et al. BMJ. 2017;356:j504.